about
miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid CancerRight pulmonary artery atresia with left circumflex coronary collaterals supplying the affected lung diagnosed by V/Q scintigraphy and CTA: a case report and review of the literature.MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: a systematic review and meta-analysis.A Rare Case of Calf Muscle Metastasis from a Non-Functional Pancreatic Neuroendocrine Carcinoma.A distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma.Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases.Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors.Anatomic and metabolic imaging of venous thromboembolism mimicking thyroid carcinoma extension.Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?Value of post-therapeutic ¹³¹I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma.Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.Afamin promotes glucose metabolism in papillary thyroid carcinoma.Dual-phase (99m)Tc-MIBI scintigraphy with delayed neck and thorax SPECT/CT and bone scintigraphy in patients with primary hyperparathyroidism: correlation with clinical or pathological variables.Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.An unusual 131I-avid adrenal metastasis from follicular thyroid carcinoma identified by 131I-SPECT/CT.Localization and identification of parapharyngeal metastases from differentiated thyroid carcinoma by 131I-SPECT/CT.Erector spinae metastases from differentiated thyroid cancer identified by I-131 SPECT/CT.Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma.More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.Rare renal metastases from differentiated thyroid carcinoma: early clinical detection and treatment based on radioiodineThe role of radionuclide lymphoscintigraphy in extremity lymphedemaPreparation and bioevaluation of (99m)Tc-HYNIC-annexin B1 as a novel radioligand for apoptosis imagingPreparation, in vitro and in vivo evaluation of (99m)Tc-Annexin B1: a novel radioligand for apoptosis imagingComparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytomaResponse to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinomaPulmonary fibrosis following radioiodine therapy of pulmonary metastases from differentiated thyroid carcinomaUnusual ¹³¹I uptake in a benign mucinous cystadenoma of the ovary in a patient with papillary thyroid cancerAbnormal ¹³¹I uptake in a benign serous ovarian cystadenoma mimicking bladder physiological uptakeCoexistant iodine-negative pleural metastasis with iodine-positive lung and bone metastases in a patient with differentiated thyroid cancerThe key role of 99mTc-MIBI SPECT/CT in the diagnosis of parathyroid adenoma: a case reportPerformance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysisClinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapyLarge thigh and buttock muscle metastases as the initial manifestation of follicular thyroid cancerSorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysisPulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131IDistant metastases from pathologically proven benign follicular nodules of the thyroid: clinicopathological features and predictors of long-term survivalClinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma
P50
Q37035505-25747C2E-B2A2-47EF-80FF-604515A648A2Q37738239-E37D4C38-8C34-4945-B158-1BEC76F8A904Q38237894-45D94C2C-ECB0-478C-94C3-22FE98215547Q38288967-2560EACA-5A52-4898-B180-244CCC0EA224Q38523324-6C271C78-07A0-4DD2-AE92-84AD35E92920Q38653990-930C57ED-9250-46F3-A967-E5328445FD79Q38757091-B97BC27B-8095-45AA-9F5B-380E3A8C3FFFQ40415771-5A647E58-B9F1-42D8-B256-24D89C5DD049Q40805907-DE100FAA-7319-465F-953A-4B72DDF4DBDBQ45939051-260F9B1E-ADC3-4EF9-A587-EAC1D55CD40BQ47647111-B705E8ED-55BE-4C9C-84D6-F0C57EFFF720Q50901388-957A4DB7-9E9C-4EB3-B88D-3C623FA93787Q51008295-B64A67FC-5C37-4138-ADCE-81FF66425218Q51284154-BD84B2FF-6A46-404D-B030-E0EAB8445F00Q51689854-37572784-9F6B-41EC-B7FE-44432E999B37Q53056442-A875BB06-70BC-40D5-988F-E180C7509011Q53134784-6CCCF906-F21B-4D9D-8E02-D84F74D266EDQ53147186-955FF6FF-423E-4A6C-98BF-4EBC7E3DDBEAQ53272032-BCA2C812-5EB0-406C-A9DB-5F30EA91496DQ53360414-3DA73E6B-F9E2-4EA4-B67A-8004F9177B4EQ53386958-614BC261-3B46-48E8-AA7D-0B672F95C414Q54367722-C31F1F04-DDFD-44F6-884F-2842294778C2Q64050300-A3193F37-1DF2-41B2-B701-BFB2DDA8917CQ80029626-375CF3FF-B593-47E5-8156-8813438BF149Q80790308-82282EF6-0D3C-47E8-AA90-7251387E6316Q81073495-41C100DE-9C20-458D-A5D4-3AD1FEC9164DQ81621945-81F801C1-E39B-4624-8F7D-3FA37B66BD14Q83038311-00C9A846-BA43-4172-80AF-57533C64E16DQ83056545-E389E968-1572-4A94-B5F2-E0BF99510D22Q83129587-A35862C8-3A97-4D94-8802-9D9214674CF4Q83396080-13556C39-2B8F-41ED-BD0C-0B46CBAF3DBFQ84770683-A1BB08A2-41B9-4FDC-A017-593CD871CB61Q85555207-81B9E465-D54F-4EFB-80F0-199D8B959B20Q85699726-3B43F225-45E2-4D53-B536-2D249E5F7050Q85833040-F61DC032-BBC1-4170-A2DA-17BF9D53178BQ86477759-D48A601D-A87B-4516-A2C5-C2F8001AB985Q86887158-7544408B-E9D9-4D96-AC31-458EF8E890E6Q90324500-90CF25C6-A42F-4576-938F-3BC47292572DQ90440673-68E35B8D-65AC-4D18-8629-7BCEEA83E16BQ91979283-EC3A561F-2637-4761-ACBA-4FA8C9B67C7D
P50
description
researcher ORCID ID = 0000-0003-3190-3037
@en
wetenschapper
@nl
name
Quan-Yong Luo
@ast
Quan-Yong Luo
@en
Quan-Yong Luo
@es
Quan-Yong Luo
@nl
type
label
Quan-Yong Luo
@ast
Quan-Yong Luo
@en
Quan-Yong Luo
@es
Quan-Yong Luo
@nl
prefLabel
Quan-Yong Luo
@ast
Quan-Yong Luo
@en
Quan-Yong Luo
@es
Quan-Yong Luo
@nl
P1153
8878652300
P31
P496
0000-0003-3190-3037